SpicyIP TV
SpicyIP's Annual Review of 2025 with developments across different categories: https://spicyip.com/2025/12/a-look-ba..... You can check out this blogpost for all the reading materials . The Annual Review Video is in three parts, divided based on three subject areas: Trademarks, Patents, and Copyright and Other IPs. In this episode 04 (Part 2 of 3), the SpicyIP team reflects upon the most significant Patent Law Developments of 2025. Developments covered 00:25- Communication Components Antenna Inc v. Ace Technologies Corp 02:25- Novenco Building And Industry A/S v. Xero Energy Engineering Solutions 03:59- Novo Nordisk As v. Dr. Reddys Laboratories Limited & Anr 05:55- F. Hoffmann-La Roche AG & Anr. v. Natco Pharma Limited 07:45- Revocation order of Novartis’ Entresto Patent 10:02- Softgel Healthcare Private Limited v. Pfizer Inc & Anr 12:45- F- Hoffmann -La Roche Ag & Anr. v. Zydus Lifesciences Limited 14:26- IP Office releases Draft Guidelines for Processing Patent Applications of AYUSH Systems and Related Inventions 16:19- A Point-Based Performance Evaluation System for Examiners and Controllers 18:04- Guidelines for Examination of Computer-Related Inventions (CRIs) 19:42- CDSCO Invites Comments to Ensure a Level Playing Field in New Drug Approval 21:56- Patent (Amendment) Rules, 2025 23:09- Amendment to Section 4 of the Patent Act consequent to the Sustainable Harnessing and Advancementof Nuclear Energy for Transforming India (SHANTI) Act, 2025 25:12- Developments concerning the Jurisdiction of the Competition Commission of India on Anti-competitive Patent Complaints 27:01- Incyte and Granules Settle Ruxolitinib Patent Infringement Dispute 28:23- Philips and Vivo Settled Their Long-Running SEP Dispute over 3G and 4G Technologies 31:27- Manpower Extension in the Indian Patent Office Updates: 03:59 After the expiry of Novo Nordisk's patent in March 2026, they filed a new set of trademark and patent infringement suits against generic companies in the Delhi High Court 26:25 The decision of the Supreme Court on Swapan Dey v CCI is out. There are discussions that CCI can now investigate violations of Competition Act by exercise of patent rights, but the operation of the DB judgement which ousted CCI’s jurisdiction, however, has not been stayed. 1. Praharsh Gour, Khushi Krishania, Wonder Drug, Generic Price: What Semaglutide’s Patent Expiry Should Really Mean for India, https://spicyip.com/2026/03/wonder-drug-generic-price-what-semaglutides-patent-expiry-should-really-mean-for-india.html 2. Praharsh Gour, [SpicyIP Tidbit] Patent’s Gone, War’s On: Inside Novo Nordisk’s Semaglutide Litigation Blitz, https://spicyip.com/2026/03/spicyip-tidbit-patents-gone-wars-on-inside-novo-nordisks-semaglutide-litigation-blitz.html 3. Yogesh Byadwal, SC to decide CCI’s Jurisdiction over abuse of Patent Rights, https://spicyip.com/2026/02/sc-to-decide-ccis-jurisdiction-over-abuse-of-patent-rights.html 4. Supreme Court decision: https://api.sci.gov.in/supremecourt/2026/124/124_2026_7_11_68257_Order_02-Feb-2026.pdfYou can find Episode 4 Part 1 here: https://youtu.be/gCJfUUtbeI0?si=4E9Kc9eUvjql_BmB Speakers: Praharsh Gour is the Editor and Researcher at SpicyIP Bharathwaj Ramakrishnan is an IP lawyer, and an Analyst at SpicyIP Ambika Aggarwal is a Ph.D. (IP Law) scholar at NALSAR University of Law, Hyderabad , and a Tech Innovation Policy Fellow (2025) and Analyst at SpicyIP Kartikeya Srivastava is a final-year law student in the LL.B. course at National Law School of India University, Bengaluru Sonisha Srinivasan is a final year law student at Christ University, and a part of the Podcast Team at SpicyIP Malobika Sen is a PhD candidate at WBNUJS, and an Analyst & 2024-25 Doctoral Fellow at SpicyIP Credits: Swaraj Paul Barooah: Producer, Director, Editor, Thumbnail Art Praharsh Gour: Host, Researcher, Speaker Sonisha Srinivasan: Editor, Speaker Bharathwaj Ramakrishnan, Ambika Aggarwal, Kartikeya Srivastava, Malobika Sen: Speakers
21 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de SpicyIP TV!